Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

United Therapeutic (NQ: UTHR )

359.51 +1.64 (+0.46%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 430,759
Open 358.40
Bid (Size) 355.40 (5)
Ask (Size) 369.39 (1)
Prev. Close 357.87
Today's Range 355.13 - 361.88
52wk Range 208.62 - 366.08
Shares Outstanding 44,891,523
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
U.S. Stock: United Therapeutics Corp
United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease. 
Via Talk Markets
Here's How Much $1000 Invested In United Therapeutics 5 Years Ago Would Be Worth Today
Via Benzinga

Performance

YTD
+58.13%
+58.13%
1 Month
+3.70%
+3.70%
3 Month
+12.72%
+12.72%
6 Month
+47.78%
+47.78%
1 Year
+56.37%
+56.37%

More News

Read More
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2024 Annual Meeting
From United Therapeutics Corporation
Via Business Wire
Key Takeaways From United Therapeutics Analyst Ratings
Via Benzinga
United Therapeutics Publishes its 2024 Corporate Responsibility and Public Benefit Report Highlighting its Progress Toward a Future Where No Patient Gets Left Behind—Ever
From United Therapeutics Corporation
Via Business Wire
The Analyst Verdict: United Therapeutics In The Eyes Of 8 Experts
Via Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth $400 Today
Via Benzinga
FDA Battles Backlog of Drug Factory Inspections Since COVID-19
Via Benzinga
Exposures Product Safety
Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark
Via Investor's Business Daily
Innovative Drugmaker Roivant Puts Up Really Healthy Sales Numbers
Via Investor's Business Daily
Ambarella To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
United Therapeutics Corporation to Present at Upcoming Investor Conferences
From United Therapeutics Corporation
Via Business Wire
Navigating 9 Analyst Ratings For United Therapeutics
Via Benzinga
Biohaven Stock Earns Relative Strength Rating Upgrade
Via Investor's Business Daily
SpringWorks Therapeutics Stock Clears Key Benchmark, Hitting 80-Plus RS Rating
Via Investor's Business Daily
Soviet Code Breaker Jim Simons' Hedge Fund Renaissance Technologies — Ozempic, Wegovy Maker Novo Nordisk Along With Nvidia, Palantir Among Top Holdings
Via Benzinga
ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday
Via Benzinga
Why Liquidia Stock Just Reversed Its Seven-Day Sprint And Crashed 38%
Via Investor's Business Daily
Rivian, Chipotle Mexican And Sirius XM Are Among Top 10 Large Cap Losers Last Week (Aug 11-Aug 17): Are The Others In Your Portfolio?
Via Benzinga
NASDAQ:UTHR is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via Chartmill
3 Biotech Stocks on Track for 50% Returns (or More) by 2028
Via InvestorPlace
UTHR Stock Earnings: United Therapeutics Misses EPS, Beats Revenue for Q2 2024
Via InvestorPlace
United Therapeutics Stock Skids On Mixed Second-Quarter Results
Via Investor's Business Daily
United Therapeutics Corporation Reports Second Quarter 2024 Financial Results
From United Therapeutics Corporation
Via Business Wire
The 3 Best 3D Bioprinting Stocks to Buy Now
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.